Robert Jay Sealock

Robert Jay Sealock

Auto-generated profile, based on publicly available information

Robert Jay Sealock

Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2010 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
RSR. J. Sealock
R. J. Sealock
GRG. Rendon
G. Rendon
HEH. B. El‐Serag
H. B. El‐Serag

26 February 2013 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RSR. J. Sealock
R. J. Sealock
JKJ. R. Kramer
J. R. Kramer
GVG. Verstovsek
G. Verstovsek
PRP. Richardson
P. Richardson
MRM. Rugge
M. Rugge
HEH. B. El‐Serag
H. B. El‐Serag
Summary: Background: Oesophageal eosinophilia (EE) is encountered in clinical practice as oesophageal biopsies are being obtained in patients with GI symptoms other than classical symptoms of eosinophilic oesophagitis (EoE). The prevalence, determinants and clinical relevance of EE identified irrespective of symptoms are unclear.Aim: To determine the prevalence and risk factors of EE with or without EoE in a nonselected group of patients undergoing endoscopy and in primary care patients.Methods: A cross‐sectional study in a single VA centre in which we obtained at least one oesophageal biopsy from patients presenting to elective endoscopy, as well as a sample of patients eligible for screening colonoscopy recruited from primary care clinics. EE was defined by >15 eosinophils in a single HPF; and EoE was defined as definite, probable or none depending on the presence of EE, acid‐suppressive therapy and oesophageal symptoms.Results: EE was identified in 33 of 1357 patients (2.4%, 95% CI: 1.7–3.4); of whom 9 had definite EoE (0.66%, 95% CI: 0.23–1.10), 17 had probable EoE (1.25%), and the only 7 patients had EE without EoE. The prevalence of EE was 2.3% among patients undergoing elective endoscopy and 0.1% among patients eligible for screening colonoscopy. Seasonal allergies (adjusted OR: 2.78; 95% CI: 1.26–6.11) and oesophageal strictures (4.50; 0.90–22.40) were associated with EE.Conclusions: The prevalence of EE was 2.3% among unselected patients presenting to endoscopy most of whom have EoE. EE was present in 0.1% in primary care patients none of whom had EoE.

30 March 2021 in Clinical Endoscopy
Verified
Journal Article
Open access
PDF file
JJJake S. Jacob
Jake S. Jacob
MLMichelle E. Lee
Michelle E. Lee
ECErin Chew
Erin Chew
ATAaron P. Thrift
Aaron P. Thrift
RSRobert J. Sealock
Robert J. Sealock
The American Society for Gastrointestinal Endoscopy (ASGE) revised its guidelines for risk stratification of patients with suspected choledocholithiasis. This study aimed to assess the diagnostic performance of the revision and to compare it to the previous guidelines. We conducted a retrospective cohort study of 267 patients with suspected choledocholithiasis. We identified high-risk patients according to the original and revised guidelines and examined the diagnostic accuracy of both guidelines. We measured the association between individual criteria and choledocholithiasis. Under the original guidelines, 165 (62%) patients met the criteria for high risk, of whom 79% had confirmed choledocholithiasis. The categorization had a sensitivity and specificity of 68% and 55%, respectively, for the detection of choledocholithiasis. Under the revised guidelines, 86 (32%) patients met the criteria for high risk, of whom 83% had choledocholithiasis. The revised categorization had a lower sensitivity and higher specificity of 37% and 80%, respectively. The positive predictive value of the high-risk categorization increased with the revision, reflecting a potential decrease in diagnostic endoscopic retrograde cholangiopancreatograpies (ERCPs). Stone visualized on imaging had the greatest specificity for choledocholithiasis. Gallstone pancreatitis was not associated with the risk for choledocholithiasis. The 2019 revision of the ASGE guidelines decreases the utilization of ERCP as a diagnostic modality and offers an improved risk stratification tool.

1 December 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
RSRobert Jay Sealock
Robert Jay Sealock
KMKhushboo Munot
Khushboo Munot

1 August 2018 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JBJessica Bernica
Jessica Bernica
SESherif Elhanafi
Sherif Elhanafi
NKNeeharika Kalakota
Neeharika Kalakota
YJYi Jia
Yi Jia
CDChristopher Dodoo
Christopher Dodoo
Mohamed O. OthmanMohamed O. Othman
Mohamed O. Othman

2 July 2018 in Medicine
Verified
Journal Article
Open access
RSRobert J. Sealock
Robert J. Sealock
ATAaron P. Thrift
Aaron P. Thrift
HEHashem B. El-Serag
Hashem B. El-Serag
JSJoseph Sellin
Joseph Sellin
Video capsule endoscopy (VCE) is a commonly used test for the evaluation of obscure gastrointestinal bleeding. However, long-term outcomes of patients undergoing VCE are unclear. To evaluate the long-term outcomes in patients undergoing VCE for suspected obscure bleeding including iron deficiency anemia (IDA), and determine the need for additional intervention for persistence or recurrence of symptoms in patients with a diagnostic as well as non-diagnostic VCE. Retrospective cohort study within a large county hospital system. We collected information on indications and findings of VCE and outcomes including further testing, bleeding, and hemoglobin (Hgb) at last follow-up through structured review of the electronic health records. VCE findings were classified as active bleeding or high potential for bleeding (P2), intermediate potential (P1) or without any disruption of the mucosa, and no potential for bleeding (P0). We compared demographic and clinical characteristics between patients with and without normal Hgb at the time of last follow up. We examined 116 patients who underwent VCEs performed for obscure gastrointestinal (GI) bleeding during 2010 to 2012 with mean duration of follow up after VCE completion of 571 days (standard deviation [SD] = 248). Abnormal VCE findings (37.9% for P1 lesions, 44.8% for P2 lesions) were seen in 106 (87.9%) patients. Additional diagnostic testing was performed in 55/116 (47.4%) (67.7% GI procedures). Hgb was restored to normal range in 59/116 (50.9%) by end of follow up which were attributed to iron supplementation and/or discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) in a majority. Twenty six of 116 patients experienced rebleeding (22.4%). The diagnostic yield of VCE is high among patients with obscure GI bleeding. More than 50% of patients achieve normal Hgb in the long term with conservative measures such as iron supplementation and the discontinuation of NSAIDs.